VitreoRetinal Technologies Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VitreoRetinal Technologies Inc.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007
We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Over the past few years's there's been no shortage of venture capital investments in companies developing potential treatments for diseases of the eye. Still, investors continue to find entrepreneurs with innovative new approaches to treat age-related macular degeneration, glaucoma and other vision-imparing diseases.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.